Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas by Jones, S et al.
Short Communication
Increased frequency of the k-ras G12C mutation in MYH
polyposis colorectal adenomas
S Jones
1, S Lambert
1, GT Williams
2, JM Best
2, JR Sampson
1 and JP Cheadle*,1
1Institute of Medical Genetics, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK;
2Department of Pathology, University of
Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK
Colorectal tumours from MYH polyposis patients display an excess of somatic G:C-T:A transversions in the adenomatous
polyposis coli gene. Here, we identify k-ras mutations in nine out of 54 (16.7%) MYH polyposis tumours. Their presence was
associated with increased dysplasia and tubulovillous morphology (P¼0.005). G:C-T:A transversions in k-ras were significantly
more frequent in MYH polyposis adenomas than in sporadic or familial adenomatous polyposis-associated tumours (Pp0.002), and
all resulted in a glycine-to-cysteine substitution at codon 12.
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MYH polyposis is an autosomal recessive multiple colorectal
adenoma and carcinoma disorder caused by inherited defects in
the MYH gene (Al-Tassan et al, 2002; Jones et al, 2002; Sampson
et al, 2003; Seiber et al, 2003). MYH functions as a base excision
repair (BER) DNA glycosylase that excises adenines misincorpo-
rated opposite 8-oxo-7,8-dihydro-20-deoxyguanosine (8-oxoG),
one of the most stable products of oxidative DNA damage
(reviewed in Cheadle and Sampson, 2003). Inactivation of the
Escherichia coli homologue of MYH leads to G:C-T:A mutations
and adenomas from MYH polyposis patients display a significant
excess of G:C-T:A transversions in the adenomatous polyposis
coli (APC) gene, as compared to sporadic or familial adenomatous
polyposis (FAP)-associated colorectal tumours (Al-Tassan et al,
2002; Jones et al, 2002). Adenomatous polyposis coli acts as a
gatekeeper for cellular proliferation in the colon and, although
mutations in APC may initiate adenoma formation, additional
somatic changes are required for progression to carcinoma
(Fearon and Vogelstein, 1990). The transition from early to
intermediate adenoma is often associated with point mutation in
the proto-oncogene k-ras (Fearon and Vogelstein, 1990). Codons
12, 13 and 61 are hotspots for mutations which reduce the GTPase
activity of the protein and result in constitutive signal transduction
(Bos, 1989). The most frequently mutated position in sporadic and
FAP-associated colorectal tumours is codon 12 (Bos, 1989). All six
nucleotide changes that result in an amino-acid substitution at this
position have oncogenic potential; however, there is structural,
biochemical (Al-Mulla et al, 1999) and clinical (Cerottini et al,
1998) evidence to suggest that the mutations have different effects.
In this study, we screened for somatic k-ras mutations in colorectal
cancers and adenomas with varying degrees of dysplasia from
patients with MYH polyposis. We found that k-ras was mutated at
a similar stage of the adenoma-to-carcinoma pathway as seen in
other colorectal tumours. All observed mutations were character-
istic of a BER defect and occurred at the same nucleotide.
MATERIALS AND METHODS
Samples
We analysed 50 adenomas and four carcinomas from five patients
harbouring biallelic germline MYH mutations (one Y165C homo-
zygote, two E466X homozygotes and two Y165C/G382D compound
heterozygotes). The size, morphology and degree of dysplasia of
each adenoma were determined according to the criteria of
Konishi and Morson (1982). DNA was extracted from tumour
samples that had been microdissected from paraffin blocks. This
study was approved by the Multicentre Research Ethics Committee
for Wales.
PCR amplification and automated sequencing
We amplified exons 1–4b of k-ras as five fragments (primer
sequences can be found at http://www.uwcm.ac.uk/study/medi-
cine/medical_genetics/research/tmg/projects/MYH3.html). Ampli-
fication products were purified by incubation with exonuclease I
and shrimp alkaline phosphatase (Amersham Biosciences, Buck-
inghamshire). Automated sequencing was carried out using the Big
Dye Terminator Cycle Sequencing kit version 3.1 (Applied
Biosystems, Cheshire). Sequencing reactions were purified using
the Montage SEQ96 Sequencing Reaction Cleanup kit (Millipore,
Hertfordshire), and analysed on an ABI PRISM 3100 Genetic
Analyser. All mutations were confirmed by sequencing at least two
independent PCR products.
Somatic k-ras mutation database and statistical analysis
We reviewed literature reports of characterised somatic k-ras
mutations in colorectal tumours. In total, data on 630 somatic
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smutations from 25 studies were included (http://www.uwcm.ac.uk/
study/medicine/medical_genetics/research/tmg/projects/MYH3.html).
We carried out statistical analyses using the Fisher’s exact test.
RESULTS
Using direct PCR product sequencing, we screened the k-ras open
reading frame for somatic mutations in 18 adenomas displaying
mild dysplasia, 30 with moderate dysplasia, two with severe
dysplasia and four carcinomas that were surgically removed from
five patients with biallelic germline MYH mutations. In total, we
identified oncogenic mutations in nine out of 54 (16.7%) colorectal
tumours (Table 1). The frequency of k-ras mutations increased
with the degree of dysplasia, from 5.6% (one out of 18) in mildly
dysplastic adenomas to 23.3% (seven out of 30) in moderately
dysplastic and 50% (one out of two) in severely dysplastic
adenomas. We did not identify any activating mutations in the
carcinomas. Mutations were significantly more frequent in
adenomas with a tubulovillous (seven out of 17, 41.2%) compared
to tubular (two out of 32, 6.3%) morphology (P¼0.005), and
tended to be more frequent in those X10mm in size (six out of 20,
30%) compared to those o5mm in size (zero out of nine, 0%)
(P¼0.08).
All nine k-ras mutations in MYH polyposis adenomas were an
identical G:C-T:A transversion at nucleotide 34, which was
predicted to replace the glycine at residue 12 with cysteine (G12C)
(Figure 1). To determine whether the spectrum of mutations
observed in MYH polyposis colorectal tumours was different from
that seen in sporadic and FAP-associated colorectal tumours, we
compiled a database of previously reported somatic k-ras codon 12
mutations (Table 2). In total, we retrieved data on 182 and 367
somatic mutations in sporadic adenomas and carcinomas, and 58
and 23 somatic mutations in FAP-associated adenomas and
carcinomas, respectively. We found a significant excess of
G:C-T:A transversions in MYH polyposis tumours as compared
to both sporadic and FAP-associated adenomas and carcinomas
(Pp0.001 and Pp0.002, respectively). G:C-T:A transversions at
both the first (34 G-T) and second (35 G-T causing G12V)
nucleotides of codon 12 are oncogenic and are frequent in both
sporadic and FAP-associated colorectal tumours. The presence of
G12C and lack of G12V in MYH polyposis adenomas compared
with other colorectal adenomas was highly significant (Pp0.002).
DISCUSSION
In this study, we identified somatic k-ras mutations in 18% (nine
out of 50) of colorectal adenomas from MYH polyposis patients,
which is similar to the frequency in FAP-associated adenomas
(Ichii et al, 1993). Our data support the reported role of p21
ras
oncogenesis in progression along the adenoma to the carcinoma
pathway (Fearon and Vogelstein, 1990), since the k-ras mutation
frequency increased from 5.6% in mildly dysplastic adenomas to
23.3% in moderately dysplastic adenomas, the frequency of k-ras
mutation increased with villous content and, the highest proportion
of mutations was observed in adenomas greater than 10mm in size.
The significant over-representation of k-ras G:C-T:A trans-
versions in MYH polyposis tumours as compared to sporadic and
FAP-associated colorectal tumours is consistent with the muta-
tional mechanism of MYH-associated tumorigenesis revealed in
our previous studies (Al-Tassan et al, 2002; Jones et al, 2002).
However, although there are two sites at codon 12 of k-ras at which
Table 1 Comparison between the frequency of k-ras mutations and
degree of dysplasia, morphology and size of colorectal tumours from MYH
polyposis patients (morphology and size for adenomas only)
%K - ras codon 12 mutation
Dysplasia grade
Mild 5.5 (1/18)
Moderate 23.3 (7/30)
Severe 50 (1/2)
Carcinoma 0 (0/4)
Morphology
Tubular 6.3 (2/32)
Tubulovillous 41.2 (7/17)
Villous 0 (0/1)
Size (mm)
o5 0 (0/9)
5–o10 14.3 (3/21)
10–o 15 30 (3/10)
X15 30 (3/10)
We analysed 50 adenomas and four carcinomas for mutations in exon 1, which
includes the mutational hotspots at codons 12 and 13. In all, 51, 46, 49 and 50
tumours were screened for variants in exons 2, 3, 4a and 4b, respectively. Figures in
parentheses indicate the number of mutations and the total number of tumours
screened.
Normal
Tumour MA22_6
G12C (34 G     T)
G G C C T C C C C A A G G C C T C C C N A A
Figure 1 Identification of the somatic k-ras codon 12 cysteine mutation
(G-T at nucleotide 34) in a moderately dysplastic MYH polyposis
colorectal adenoma (tumour MA22_6). Sequences are shown in the
reverse direction and the arrow indicates the position of the mutation.
Table 2 Spectrum of published k-ras codon 12 mutations in sporadic, FAP-associated and MYH polyposis colorectal tumours
Frequency of codon 12 mutations (%)
Tumour type Ala (GCT) Arg (CGT) Asp (GAT) Cys (TGT) Ser (AGT) Val (GTT)
Sporadic adenomas (n¼182) 4.4 (8) 8.2 (15) 31.9 (58) 13.2 (24) 10.4 (19) 31.9 (58)
Sporadic carcinomas (n¼367) 9 (33) 1.6 (6) 35.4 (130) 13.9 (51) 14.5 (53) 25.6 (94)
FAP adenomas (n¼58) 5.2 (3) 3.4 (2) 37.9 (22) 19 (11) 8.6 (5) 25.9 (15)
FAP carcinomas (n¼23) 0 (0) 0 (0) 65.2 (15) 17.4 (4) 8.7 (2) 8.7 (2)
MYH polyposis adenomas (n¼9) 0 (0) 0 (0) 0 (0) 100 (9) 0 (0) 0 (0)
The cysteine mutation is significantly more frequent in MYH polyposis than in sporadic or FAP-associated adenomas (Pp0.002). The actual number of mutations is indicated in
parentheses.
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mutations were at nucleotide 34, leading to a glycine-to-cysteine
substitution. This may reflect an increased susceptibility to
oxidative damage at the first base of codon 12 or repair enzyme
specificity. Different mutations at codon 12 of k-ras are thought to
have different biological effects and Cerottini et al (1998) reported
that G12C is associated with reduced survival in patients with
colon cancer. Although the somatic genetic changes that effect
prognosis are likely to be complex, these clinical findings are
consistent with biochemical and structural data which demonstrate
that the GTPase activity, affinity for GTP and interactions
with other proteins vary, depending upon the precise nature of
mutations affecting k-ras (Al-Mulla et al, 1999). Further studies are
therefore warranted to determine whether the specific targeting of
k-ras in the adenomas of patients with MYH polyposis influences
later clinical outcome.
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